Manetti Mirko, Guiducci Serena, Romano Eloisa, Avouac Jérôme, Rosa Irene, Ruiz Barbara, Lepri Gemma, Bellando-Randone Silvia, Ibba-Manneschi Lidia, Allanore Yannick, Matucci-Cerinic Marco
Arthritis Res Ther. 2013 Oct 25;15(5):R165. doi: 10.1186/ar4349.
Microvascular damage and defective angiogenesis and vasculogenesis have a major role in the pathogenesis of systemic sclerosis (SSc). Epidermal growth factor-like domain 7 (EGFL7) is a proangiogenic molecule which is predominantly expressed and secreted by endothelial cells and their progenitors and controls vascular development and integrity. In this study, we investigated the possible involvement of EGFL7 in SSc.
Serum EGFL7 levels from 60 patients with SSc and 35 age- and sex-matched healthy controls were examined by colorimetric sandwich enzyme-linked immunosorbent assay. The expression of EGFL7 in forearm skin biopsies (n = 16 SSc, n = 10 controls), cultured dermal microvascular endothelial cells (MVECs) (n = 3 SSc, n = 3 controls) and late-outgrowth peripheral blood endothelial progenitor cell (EPC)-derived endothelial cells (n = 15 SSc, n = 8 controls) was investigated by immunofluorescence and Western blotting.
Serum EGFL7 levels were detectable in 68.6% of healthy controls and 45% of SSc cases (P < 0.05). Circulating levels of EGFL7 were significantly decreased in SSc patients compared with healthy controls (P = 0.01). Serum levels of EGFL7 were significantly lower in both limited cutaneous SSc and diffuse cutaneous SSc patients than in controls (P = 0.02 and P = 0.04, respectively). In SSc, decreased serum EGFL7 levels were significantly correlated with the severity of nailfold capillary abnormalities. Patients with the most severe capillary changes and digital ulcers had serum EGFL7 levels significantly lower than healthy controls, while the EGFL7 levels did not differ significantly between controls and SSc patients with less capillary damage and lack of digital ulcers. Endothelial EGFL7 expression was strongly downregulated or even almost completely undetectable in SSc-affected dermis compared with controls (P < 0.001). In cultured SSc dermal MVECs and late-outgrowth peripheral blood EPC-derived endothelial cells, EGFL7 was significantly downregulated compared with cells obtained from healthy subjects (P < 0.01 and P < 0.001, respectively).
Our findings suggest that the loss of EGFL7 expression in endothelial cells and their progenitors might play a role in the development and progression of peripheral microvascular damage and the defective vascular repair process characteristic of SSc.
微血管损伤以及血管生成和血管发生缺陷在系统性硬化症(SSc)的发病机制中起主要作用。表皮生长因子样结构域7(EGFL7)是一种促血管生成分子,主要由内皮细胞及其祖细胞表达和分泌,控制血管发育和完整性。在本研究中,我们调查了EGFL7在SSc中的可能作用。
采用比色夹心酶联免疫吸附测定法检测60例SSc患者和35例年龄及性别匹配的健康对照者的血清EGFL7水平。通过免疫荧光和蛋白质印迹法研究EGFL7在前臂皮肤活检组织(n = 16例SSc患者,n = 10例对照者)、培养的真皮微血管内皮细胞(MVECs)(n = 3例SSc患者,n = 3例对照者)以及晚期外周血内皮祖细胞(EPC)来源的内皮细胞(n = 15例SSc患者,n = 8例对照者)中的表达。
68.6%的健康对照者和45%的SSc患者血清中可检测到EGFL7水平(P < 0.05)。与健康对照者相比,SSc患者循环中的EGFL7水平显著降低(P = 0.01)。局限性皮肤型SSc患者和弥漫性皮肤型SSc患者的血清EGFL7水平均显著低于对照者(分别为P = 0.02和P = 0.04)。在SSc中,血清EGFL7水平降低与甲襞毛细血管异常的严重程度显著相关。毛细血管变化最严重且有指端溃疡的患者血清EGFL7水平显著低于健康对照者,而毛细血管损伤较轻且无指端溃疡的SSc患者与对照者之间的EGFL7水平无显著差异。与对照者相比,SSc患者受影响的真皮中内皮细胞EGFL7表达强烈下调,甚至几乎完全无法检测到(P < 0.001)。在培养的SSc真皮MVECs和晚期外周血EPC来源的内皮细胞中,与从健康受试者获得的细胞相比,EGFL7显著下调(分别为P < 0.01和P < 0.001)。
我们的研究结果表明,内皮细胞及其祖细胞中EGFL7表达的缺失可能在SSc外周微血管损伤的发生发展以及特征性的血管修复缺陷过程中起作用。